Recent findings suggest that individuals on Medicare are receiving the newly approved Alzheimer’s medications at a lower rate than federal officials had anticipated.
This discrepancy highlights potential gaps in access to critical treatments for those affected by Alzheimer’s disease.
As discussions continue around Medicare's role in providing necessary care, the situation calls for closer examination of the factors influencing medication distribution.